NICE

News

AbbVie's ovarian cancer drug Elahere gets NHS green light

AbbVie's Elahere has become the first new NHS therapy in more than 20 years for resistant ovarian cancer, providing an alternative to chemotherapy.

News

NICE changes stance on Genmab's cervical cancer drug

After saying it couldn't recommend Genmab's cervical cancer therapy Tivdak for use by the NHS, reimbursement authority NICE has had a change of heart.

News

NICE backs stomach cancer, PAH drugs for NHS use

AZ's Imfinzi is the first NHS immunotherapy for a form of stomach cancer, while MSD's Winrevair gets a green light for rare respiratory disease PAH.

News

Two hands pointing to each other index finger to index finger in a Chinese puzzle, on dark blue background

Joint MHRA/NICE pathway 'benefits industry over patients'

LSE pharma policy expert contends the MHRA/NICE aligned pathway is weighted towards industry, and calls for an assessment of its impact on the NHS.

News

Deal finally unlocks NHS access to ITF's Duchenne drug

After nearly two years of wrangling, ITF's Duvyzat can be used by the NHS to treat people living with Duchenne muscular dystrophy.

News

NICE backs UCB drug as first uncontrolled gMG therapy

UCB's Rystiggo can be used by the NHS as a backup treatment for people with the rare autoimmune and neuromuscular disease gMG, says NICE.

AbbVie's ovarian cancer drug Elahere gets NHS green light

NICE changes stance on Genmab's cervical cancer drug

NICE backs stomach cancer, PAH drugs for NHS use

Joint MHRA/NICE pathway 'benefits industry over patients'

Deal finally unlocks NHS access to ITF's Duchenne drug

NICE backs UCB drug as first uncontrolled gMG therapy

ASCO 2026: Chinese firms take a front seat in oncology, with...

Discover a new era of healthcare panel engagement: Grounded ...

NICE

Editor's Picks